Exonate launches diabetic macular oedema trial
Study of lead asset is part of a collaboration with Janssen Pharmaceuticals
Read More
Tag: Diabetic Macular Oedema
Exonate fundraises £1.5 million
Exonate has successfully fundraised £1.5 million to accelerate development of its lead product – an eye drop treatment for retinal neovascular diseases.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
